U.S. market Closed. Opens in 3 hours 41 minutes

ALLO | Allogene Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenue95.00K243.00K38.49MN/AN/AN/AN/A
Cost of Revenue242.91M16.73M13.06M11.54M5.03M1.50MN/A
Gross Profit-242.82M-16.48M25.42M-11.54M-5.03M-1.50MN/A
Operating Expenses327.83M335.69M294.28M258.24M202.01M192.84M2.00K
Selling, General & Admin71.67M79.31M74.11M65.26M57.47M40.98M2.00K
Research & Development242.91M256.39M220.18M192.99M144.53M151.86MN/A
Other Operating Expenses13.24M-1.75M-2.93M-1.14M-268.00K-21.21MN/A
Operating Income-327.74M-335.45M-255.79M-258.24M-202.01M-192.84M-2.00K
Other Expenses / Income472.00K-4.88M-1.86M8.02M17.08M-18.78M-22.00K
Before Tax Income-327.26M-332.63M-257.00M-250.22M-184.93M-211.62M-2.00K
Income Tax ExpensesN/A-2.82M-12.17M-16.75M-331.00K-117.00K-24.00K
Net Income-327.26M-329.81M-244.84M-233.47M-184.59M-211.50M-2.00K
Interest ExpensesN/AN/AN/AN/AN/A3.36MN/A
Basic Shares Outstanding156.93M143.15M135.82M120.37M101.06M28.95M117.93M
Diluted Shares Outstanding156.93M143.15M135.82M120.37M101.06M28.95M117.93M
EBITDA-300.29M-321.24M-169.74M-250.81M-179.90M-206.76M22.00K
EBITDA Margin-316,097.89%-132,197.94%-441.00%0.00%0.00%0.00%0.00%
EBIT-327.26M-332.63M-257.00M-250.22M-184.93M-208.26M-26.00K
EBIT Margin-344,489.47%-136,885.60%-667.74%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙